Kaiser Foundation Health Plan, Inc. successfully finalized a $142.1 damages verdict against Pfizer for off-label promotion of the anti-seizure medication Neurontin. The case was part of a multidistrict litigation (MDL) in the U.S. District Court for the District of Massachusetts (In re Neurontin Marketing, Sales Practice and Product Liability Litigation, MDL-1629) which included third-party payer suits and personal injury lawsuits alleging suicide, attempted suicide and other personal injuries as a result of use of Neurontin. The verdict was affirmed by the U.S. Court of Appeals for the First Circuit in April. This month, the U.S. Supreme Court denied Pfizer's petition for certiorari, effectively finalizing the verdict.
RSS Feed
